6505--Emtricitabine/Tenofovir Disoproxil Fumarate Tablets

The Department of Veterans Affairs National Acquisition Center is seeking to procure Emtricitabine 200mg/Tenofovir Disoproxil Fumarate 300mg Tablets through a competitive solicitation. The pharmaceutical contract aims to supply 30-count tablet bottles, with an estimated annual usage of 91,583 bottles across multiple federal agencies including VA, DoD, Bureau of Prisons, and Indian Health Service. Pharmaceutical vendors must meet stringent requirements, including FDA approval, current Good Manufacturing Practices (cGMP), unique National Drug Code (NDC) numbers, and compliance with Drug Supply Chain Security Act (DSCSA) regulations. The procurement will utilize a lowest price technically acceptable evaluation criteria, with proposals due by May 16, 2025, at 2:30 PM CT. Offerors are required to submit pricing for a base year and four one-year option periods, and include a mandatory 0.5% Cost Recovery Fee in their pricing structure.

The solicitation is not designated as a specific small business set-aside, but has a size standard of 1,300 employees for potential participants. The contract will be distributed through government Prime Vendor contractors, with McKesson Corporation identified as a primary distributor. While specific award values are not explicitly stated, the contract's scope suggests a significant pharmaceutical procurement across multiple federal healthcare systems. The contract timeline includes a base year with four potential one-year extension periods, providing a potential five-year total contract duration. Distribution will be managed through established government distribution channels, ensuring widespread availability of the pharmaceutical product across various federal healthcare networks. The procurement falls under NAICS Category 325412 for Pharmaceutical Preparation Manufacturing and PSC Category 6505 for Drugs and Biologicals, reflecting the specialized nature of the contract.